为危重症患者设定β-内酰胺类治疗窗:是否存在下限甚至上限?
本文为叙述性综述,汇总β-内酰胺类在危重症患者中的药代/药效阈值证据,以支持个体化治疗药物监测。实验数据提示β-内酰胺浓度高于病原体MIC的时间需≥给药间隔的40–60%,但临床数据提示更高浓度可能更优。危重症最初48小时,游离β-内酰胺浓度全程≥最可能病原体(通常基于铜绿假单胞菌)敏感折点是合理的;48小时后最低可接受浓度可调整为全程1–2×所观察到的病原体MIC。神经毒性是β-内酰胺类主要剂量依赖性不良反应,但证据尚不足以将特定药物浓度与更高风险关联。
要点
- 危重症最初48小时:游离β-内酰胺浓度全程≥最可能病原体(通常基于铜绿假单胞菌)敏感折点,是合理的治疗下限。
- 48小时后:最低可接受浓度可个体化调整为全程1–2×所观察到的病原体MIC(常为更敏感病原体)。
- 实验数据:β-内酰胺浓度高于MIC的时间需≥给药间隔的40–60%,但临床数据提示更高浓度可能更优。
- 神经毒性是β-内酰胺类主要剂量依赖性不良反应,但证据尚不足以将特定药物浓度与更高风险关联。
- 实施治疗药物监测需明确治疗窗,即何种药物浓度会促使临床医生上调或下调剂量。
适用人群与场景
- 危重症患者(ICU人群),存在β-内酰胺类药代动力学高个体间变异,考虑个体化治疗药物监测者。
诊断标准与关键阈值
- 实验数据阈值:β-内酰胺浓度高于病原体MIC的时间≥给药间隔的40–60%。
- 危重症最初48小时下限:游离β-内酰胺浓度全程≥最可能病原体(通常基于铜绿假单胞菌)的敏感折点。
- 48小时后下限:全程1–2×所观察到的病原体MIC(常为更敏感病原体)。
- 毒性上限(ceiling):神经毒性为主要剂量依赖性不良反应,但证据不足以将特定药物浓度与更高风险关联。
- 原文未提及具体评分界值或启动/停止阈值。
处置流程与药物剂量
- 第一步:明确β-内酰胺治疗窗,即何种药物浓度会促使临床医生上调或下调剂量。
- 第二步:危重症最初48小时,目标为游离β-内酰胺浓度全程≥最可能病原体(通常基于铜绿假单胞菌)敏感折点。
- 第三步:48小时后,将最低可接受浓度个体化调整为全程1–2×所观察到的病原体MIC(常为更敏感病原体)。
- 第四步:监测神经毒性(主要剂量依赖性不良反应),但原文未给出具体药物浓度阈值。
- 原文未提及具体药物剂量、单位、途径、频次或疗程。
红旗征与不能漏的情况
- 神经毒性:β-内酰胺类主要剂量依赖性不良反应,需监测,但证据不足以将特定药物浓度与更高风险关联。
研究设计与关键结果
- 研究类型:叙述性综述(narrative review),汇总临床前、转化及临床数据。
- 实验数据:β-内酰胺浓度高于MIC的时间≥给药间隔的40–60%为所需,但临床数据提示更高浓度可能更优。
- 危重症最初48小时:游离β-内酰胺浓度全程≥最可能病原体(通常基于铜绿假单胞菌)敏感折点合理。
- 48小时后:最低可接受浓度可个体化为全程1–2×所观察到的病原体MIC。
- 神经毒性为主要剂量依赖性不良反应,但证据不足以将特定药物浓度与更高风险关联。
证据类型、等级与局限
- 证据类型:叙述性综述,汇总临床前、转化及临床数据。
- 局限:原文未明确列出;综述本身非系统评价,未提供定量合并或偏倚评估。
对床旁实践的改变
- 可改变的做法:危重症最初48小时,以游离β-内酰胺浓度全程≥最可能病原体(通常基于铜绿假单胞菌)敏感折点作为治疗下限指导剂量调整。
- 可改变的做法:48小时后,将最低可接受浓度个体化调整为全程1–2×所观察到的病原体MIC。
- 不改变的做法:不能仅凭特定药物浓度设定神经毒性上限,因证据不足以将特定浓度与更高风险关联。
- 适用人群:危重症患者,考虑个体化治疗药物监测者;原文未提及不适用人群。
- 常见陷阱:原文未提及。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Beta-lactam antibiotics exhibit high interindividual variability in drug concentrations in patients with critical illness which led to an interest in the use of therapeutic drug monitoring to improve effectiveness and safety. To implement therapeutic drug monitoring, it is necessary to define the beta-lactam therapeutic range-in essence, what drug concentration would prompt a clinician to make dose adjustments up or down. This objective of this narrative review was to summarize evidence for the "floor" (for effectiveness) and "ceiling" (for toxicity) for the beta-lactam therapeutic range to be used with individualized therapeutic drug monitoring.
DATA SOURCES: Research articles were sourced from PubMed using search term combinations of "pharmacokinetics," "pharmacodynamics," "toxicity," "neurotoxicity," "therapeutic drug monitoring," "beta-lactam," "cefepime," "meropenem," "piperacillin/tazobactam," "ICU," and "critical illness."
STUDY SELECTION: Articles were selected if they included preclinical, translational, or clinical data on pharmacokinetic and pharmacodynamic thresholds for effectiveness and safety for beta-lactams in critical illness.
DATA SYNTHESIS: Experimental data indicate a beta-lactam concentration above the minimum inhibitory concentration of the organism for greater than or equal to 40-60% of the dosing interval is needed, but clinical data indicate that higher concentrations may be preferrable. In the first 48 hours of critical illness, a free beta-lactam concentration at or above the susceptibility breakpoint of the most likely pathogen for 100% of the dosing interval would be reasonable (typically based on Pseudomonas aeruginosa). After 48 hours, the lowest acceptable concentration could be tailored to 1-2× the observed minimum inhibitory concentration of the organism for 100% of the dosing interval (often a more susceptible organism). Neurotoxicity is the primary dose-dependent adverse effect of beta-lactams, but the evidence remains insufficient to link a specific drug concentration to greater risk.
CONCLUSIONS: As studies advance the understanding of beta-lactam exposure and response in critically ill patients, it is essential to clearly define the acceptable therapeutic range to guide regimen selection and adjustment.
参考来源
- Barreto EF, Webb AJ, Pais GM, et al. Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling? Crit Care Explor. 2021. PMID: 34136822. doi:10.1097/CCE.0000000000000446
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。